Navigation Links
ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia
Date:11/13/2007

LEUVEN, Belgium, November 14 /PRNewswire/ --

- Key Research Findings Published in the Leading Medical Journal `Blood' Validate Drug Target

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, announces today that it will progress with the development of its novel anti-VPAC(1) antibody for the treatment of thrombocytopenia, including chemotherapy-induced thrombocytopenia.

Thrombocytopenia, which is the reduced number of platelets in blood, is a common severe side effect of chemotherapy and increases the risk of bleeding and severity of haemorrhage, therefore causing the delay or even discontinuation of treatment in cancer patients. There is a high medical need to find a therapeutic that could reduce thrombocytopenia by accelerating platelet production. Blood transfusion, the current standard of care for this condition, offers only a temporary solution for these patients and is associated with significant cost and risk.

Researchers at the University of Leuven and ThromboGenics have developed a novel therapeutic approach, showing that the inhibition of VPAC could stimulate the production of platelets. ThromboGenics has now identified and selected a lead antibody against VPAC to enter preclinical development. VPAC is a receptor present at the surface of bone marrow cells called megakaryocytes, which, when mature, produce platelets. Research published yesterday in Blood describes how the inhibition of VPAC could promote megakaryocyte differentiation. Blood is the official journal of the American Society of Hematology (ASH).

Prof. Desire Collen, CEO and Chairman of ThromboGenics, commented: "Thrombocytopenia is a severe complication of cancer patients receiving chemotherapy, and for which there is little therapeutic alternative. I am very pleased to advance our thrombocytopenia programme to preclinical development, which I hope will confirm the potential of our approach published in Blood. This highlights the novelty of our programme compared to other agents in development for treatment of this serious condition."

Reference

Blood First Edition Paper, prepublished online, 13 November 2007, PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications.

Kathleen Freson, Karen Peeters, Rita De Vos, Christine Wittevrongel, Chantal Thys, Marc F Hoylaerts, Jos Vermylen and Chris Van Geet.

(1) VPAC: Vasoactive Intestinal Peptide/Pituitary Adenylyl Cyclase Activating Peptide Receptor-1

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which is expected to proceed to Phase I clinical trials by the end of 2007. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.

For further information please contact:

ThromboGenics

Prof Desire Collen, CEO

Patrik De Haes, COO

Tel: +32(0)16-34-61-94

Citigate Dewe Rogerson

Valerie Auffray/ David Dible / Amber Bielecka

Tel: +44(0)207-638-95-71

valerie.auffray@citigatedr.co.uk


'/>"/>
SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. PA Department of Public Welfare Begins Outreach to Medical Assistance Consumers Following Burglary at State Office Building
3. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
4. Most comprehensive study of mercury in dental fillings begins
5. Eye Safety Begins at Home
6. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
7. OmniGuide Begins European Commercialization
8. From Microscope to Stethoscope: the MUHCs distinguished public lecture series begins a second seaso
9. From microscope to stethoscope: The MUHCs public lecture series begins its 2nd season tomorrow
10. North Shore-LIJ Health System Begins Online Posting of Hospital Infection Rates, Other Performance Information
11. Healthy Weight Loss Begins With What You Permit to Enter Your Mind, More So Than Even Your Mouth!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... With ... on the challenge of providing additional organic alternatives for customers who have grown ... the brand’s new line of all-natural activated charcoal products, Moody Zook Chief Executive ...
(Date:1/13/2017)... ... 2017 , ... An inventor from Virginia Beach, Va., is always on the ... diversify my outfits, so he decided to design something that enhances the look of ... of a belt to allow for quick, easy changing of its look. This not ...
(Date:1/13/2017)... ... 2017 , ... "We wanted to create a design for orthodontic appliances that ... from Virginia Beach, Va. , They created a prototype for the patent-pending BRACE FACERS ... braces to be customized to suit personal tastes. They can be used to create ...
(Date:1/13/2017)... ... January 13, 2017 , ... On January 11th, Finnleo ... MN, with the official send-off from Orchestra Hall in Minneapolis on Saturday, January ... Orchestra’s Music Director, leading the official launch of the sauna. After leaving Minneapolis, ...
(Date:1/13/2017)... ... January 13, 2017 , ... The Joint Corp. was ... franchise ranking. Recognized by entrepreneurs and franchisors as a top competitive measurement, the ... areas including financial strength and stability, growth rate, and brand power. , “It ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... January 16, 2017 ... Product Type (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl ... Beverages, Surface Coatings & Paints), Region - ... the market was valued at USD 4.51 ... reach USD 6.41 Billion by 2021, at ...
(Date:1/16/2017)... Bill is an internationally experienced medical device ... leadership positions with global medical device companies, including Smith & Nephew, ... launching new products and building successful businesses in the sector and ... and North America . ... Educated at the University of ...
(Date:1/16/2017)... -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased to announce ... to its Board of Directors. He is the President ... LLC . He is also the Chief Investment Officer ... firm with over $1.5 billion under management. ... analysis and portfolio management. He began his career in ...
Breaking Medicine Technology: